Inhibitor for inhibiting expression of inhibin beta e gene and use thereof
By developing RNAi agents or RNAs targeting the INHBE gene, duplexes complement each other with the target gene mRNA, induced RNA-induced silencing complex-mediated cleavage, significantly inhibiting INHBE gene expression, solving the problem of difficult to effectively inhibit INHBE expression in the prior art, and improving the therapeutic effect on diseases such as metabolic syndrome.
WO2025082057A1 Publication Date: 2025-04-24RUNJIA (SHANGHAI) PHARM TECH CO LTD
5 Cites 3 Cited by
Patent Information
- Application Number
- PCT/CN2024/115763
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-16
- Filing Date
- 2024-08-30
- Publication Date
- 2025-04-24
AI Technical Summary
Technical Problem
The prior art is difficult to effectively inhibit the expression of the inhibitin Beta E gene (INHBE), making it difficult to treat related diseases such as metabolic syndrome.
Method used
A RNAi agent or RNA is developed to target the INHBE gene, which is complementary to the target gene mRNA by forming duplexes, thereby inducing RNA-induced silencing complex-mediated cleavage, significantly inhibiting INHBE gene expression.
Benefits of technology
By targeting the degradation of INHBE mRNA, the expression of INHBE gene is significantly inhibited, and the treatment effect on diseases such as metabolic syndrome is improved.
✦ Generated by Eureka AI based on patent content.
Abstract
A dsRNA and double-stranded RNAi agent for inhibiting the expression of INHBE and a use thereof. The dsRNA and the double-stranded RNAi agent can be used for inhibiting the expression of INHBE to prevent and treat a metabolic disorder (such as a metabolic syndrome).
Need to check novelty before this filing date? Find Prior Art